Evidence map›Paper›PMID 40644455›Full record

ArticlePLOS global public health2025

Dynamic modeling of mortality risk factors in Ebola virus disease using logistic regression on unbalanced panel data from a randomized controlled trial in the Democratic Republic of Congo.

Leader Lawanga Ontshick, Jepsy Yango, Ange Mubiala Yaya, Olivier Tshiani Mbaya, Joule Madinga Twan, Jean-Michel Nsengi Ntamabyaliro, Rosine Ali, Patrick Mutombo Lupola, Joseph-Desiré Bukweli, Sifa Marie-Joelle Muchanga and 4 more

Abstract read
In one paragraph

Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Leader Lawanga OntshickDepartment of Epidemiology and Global Health, National Institute of Biomedical Research, Kinshasa, Democratic Republic of Congo.ORCID https://orcid.org/0009-0005-5970-519X
Jepsy YangoDepartment of Epidemiology and Global Health, National Institute of Biomedical Research, Kinshasa, Democratic Republic of Congo.ORCID https://orcid.org/0000-0002-1258-7481
Ange Mubiala YayaImmunology Department, National Institute of Biomedical Research, Kinshasa, Democratic Republic of Congo.
Olivier Tshiani MbayaImmunology Department, National Institute of Biomedical Research, Kinshasa, Democratic Republic of Congo.
Joule Madinga TwanDepartment of Epidemiology and Global Health, National Institute of Biomedical Research, Kinshasa, Democratic Republic of Congo.
Jean-Michel Nsengi NtamabyaliroDepartment of Pharmacology and Therapeutics, University of Kinshasa, Kinshasa, Democratic Republic of Congo.
Rosine AliDepartment of Parasitology, National Institute of Biomedical Research, Kinshasa, Democratic Republic of Congo.
Patrick Mutombo LupolaDepartment of Epidemiology and Global Health, National Institute of Biomedical Research, Kinshasa, Democratic Republic of Congo.ORCID https://orcid.org/0000-0002-4541-5723
Joseph-Desiré BukweliDepartment of Mathematics, Statistics and Computer Science, University of Kinshasa, Kinshasa, Democratic Republic of Congo.
Sifa Marie-Joelle MuchangaDepartment of Obstetrics and Gynecology, Kinshasa, Democratic Republic of the Congo.
Gaston Tona LuteteDepartment of Pharmacology and Therapeutics, University of Kinshasa, Kinshasa, Democratic Republic of Congo.
Placide Mbala KiangebeniDepartment of Epidemiology and Global Health, National Institute of Biomedical Research, Kinshasa, Democratic Republic of Congo.
Sabue MulanguImmunology Department, National Institute of Biomedical Research, Kinshasa, Democratic Republic of Congo.ORCID https://orcid.org/0000-0002-2722-2637
Rostin Mabela Makengo MatendoDepartment of Mathematics, Statistics and Computer Science, University of Kinshasa, Kinshasa, Democratic Republic of Congo.

Funding

Emerging and Re-Emerging Pathogens Research Training Program in DRC (EREP-RTP-DRC)D43TW012736 · FIC · INSTITUT NATIONAL / RECHERCHE BIOMEDICAL · PI Jean-Jacques Tamfum Muyembe-Tamfum, JEAN BISIMWA NACHEGA · 2024 to 2026
$972k
FIC NIH HHS D43 TW012736
6 · The paper itself

Abstract

Ebola Virus Disease (EVD) remains a significant public health threat, particularly in sub-Saharan Africa. During the 10th Ebola outbreak in the Democratic Republic of Congo (DRC), the Pamoja Tulinde Maisha clinical trial (PALM-RCT) provided a unique opportunity to evaluate new therapeutic interventions. Despite these advances, limited knowledge exists regarding the dynamic evolution of mortality risk factors in EVD patients. This study aimed to model risk factors associated with mortality using logistic regression on unbalanced panel data from patients enrolled in this trial.We conducted a retrospective secondary analysis of longitudinal data from 617 EVD patients included in the PALM-RCT. Data were collected at five time points: Day0 (admission), Day7, Day14, Day21, and Day28. A binary logistic regression model was applied at each time point to identify significant predictors of mortality. The Hosmer-Lemeshow test was used to assess model calibration and internal validation. At Day0 (admission), six significant predictors of mortality were identified: viral load (RT-PCR cycle threshold value), creatinine, alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), haemorrhage, shortness of breath, and conjunctivitis. By Day7, five predictors emerged: sodium, ASAT, coma, abdominal pain, and shortness of breath. At Day14, two predictors remained significant: ASAT and mental state changes. No significant predictors were identified at Day21 and Day28. The dynamic nature of these risk factors highlights the importance of continuous monitoring throughout the clinical course of EVD.Our study demonstrates that mortality risk factors in EVD patients evolve over time, suggesting that a dynamic approach to patient monitoring is critical. Early risk factors such as viral load and renal function should guide initial interventions, while neurological symptoms and electrolyte imbalances require attention in later stages. These findings support a personalized approach to EVD management, where clinical care is adjusted based on real-time clinical data to improve patient outcomes.

Identifiers

PMID40644455
PMCPMC12250521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.